Trials
5 active
9 in total · 5 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Atrial Fibrillation (AF) (2 trials), Venous Thromboembolism (VTE), Peripheral Artery Disease (PAD), End-Stage Kidney Disease (ESKD)
- Main trialPhase 3
- “This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. When this happens, blood cannot move smoothly through the heart; it can slow down or pool in one spot, which can lead to the formation of blood clots. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how effective and safe REGN7508 and REGN9933, individually, are in preventing…”In the company’s words, NCT07430956 on ClinicalTrials.gov
- Other names
- amrecibart
Other drugs for Atrial Fibrillation (AF)
- MilvexianJohnson & Johnson (Janssen) · Bristol Myers Squibb · Phase 3
- CenvacibartRegeneron · Phase 3
- AbelacimabAnthos Therapeutics, Inc. · Phase 3
- AbelacimabNovartis · Phase 3
- AP31969Acesion Pharma · Phase 2
- BudiodaroneXyra, LLC · Phase 2
Coming up5
- 9 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- 2 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
- 28 Mar 2029Phase 3 trial completes · ClinicalTrials.gov
- 25 Jun 2029Phase 3 trial completes · ClinicalTrials.gov
- 18 Aug 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 28 Mar 2029 | Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | |
| Phase 3Recruiting | 25 Jun 2029 | Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC) | |
| Phase 3Recruiting | 18 Aug 2029 | Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease | |
| Phase 2Recruiting | 9 Feb 2027 | Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | |
| Phase 1Recruiting | 2 Apr 2027 | Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis | |
| Phase 2Completed | 27 May 2024 | A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants | |
| Phase 2Completed | 27 Mar 2026 | A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) | |
| Phase 1Completed | 4 Apr 2023 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9933 in Adult Healthy Volunteers | |
| Phase 1Completed | 7 Apr 2025 | Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026